Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
XPro1595
product3 mentionslast seen Oct 29, 2026
Dominant-Negative Tumor Necrosis Factor platform designed to selectively neutralize soluble TNF and reduce neuroinflammation.
Relationships 6
- INmune Bio Inc.developsXPro159599% confidence3 sources
- XPro1595applies toAlzheimer's disease treatment95% confidence1 source
- XPro1595applies toearly Alzheimer's disease treatment92% confidence1 source
- XPro1595applies torare disease treatment85% confidence1 source
- XPro1595applies toinflammation and immunology treatment85% confidence1 source
- U.S. Food and Drug AdministrationapprovesXPro159580% confidence1 source
Relationship
INmune Bio Inc.developsXPro1595
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 29, 2026Inmune Bio, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform
- filingSEC EDGAROct 21, 2026Inmune Bio, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF
- newsPR NewswireOct 14, 2026INmune Bio Inc. and Quantum Computing Inc. Partner to Apply Quantum Optimization and AI to Advance Alzheimer's Drug Research and Explore New Applications for XPro ™
XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's disease